Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases

BACKGROUND: Nivolumab has been approved for use in advanced gastric cancer (GC) after third-line chemotherapy in Japan. However, it remains difficult to predict favorable nivolumab response before treatment. METHODS: We evaluated the clinical course with a focus on the chronological changes in neutr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Naohiko, Kinami, Shinichi, Fujita, Jun, Kaida, Daisuke, Tomita, Yasuto, Miyata, Takashi, Fujita, Hideto, Takamura, Hiroyuki, Ueda, Nobuhiko, Kosaka, Takeo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798180/
https://www.ncbi.nlm.nih.gov/pubmed/33112554
http://dx.doi.org/10.31557/APJCP.2020.21.10.2955

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798180/
https://www.ncbi.nlm.nih.gov/pubmed/33112554
http://dx.doi.org/10.31557/APJCP.2020.21.10.2955

Ejemplares similares